Neurocrine Biosciences (NBIX) : $4.47 million worth of transactions were on upticks in Neurocrine Biosciences (NBIX), compared to $3.75 million on downticks. The ratio between the two was 1.19, whereas, the net money flow stood at a healthy $0.72 million on Tuesdays session. The consistent buying on upticks in the stock accounted for $0.1million worth of trades. The total money flow into the stock stood at $0.1 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.14%. The stock was trading at $48.57, with a drop of $0.07 over the previous days close. The stock recorded -0.02% for the week.
The company Insiders own 4.8% of Neurocrine Biosciences shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -24.89% . During last six month period, the net percent change held by insiders has seen a change of -24.89%. In an insider trading activity, Lloyd-Smith Malcolm, officer (Chief Regulatory Officer) of Neurocrine Biosciences Inc, unloaded 9,000 shares at an average price of $50 on May 31, 2016. The total amount of the transaction was worth $450,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Shares of Neurocrine Biosciences Inc. rose by 5.58% in the last five trading days and 0.04% for the last 4 weeks. Neurocrine Biosciences Inc. is up 8.23% in the last 3-month period. Year-to-Date the stock performance stands at -14.44%.
Neurocrine Biosciences (NASDAQ:NBIX): On Tuesdays trading session , Opening price of the stock was $48.98 with an intraday high of $49.24. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $47.85. However, the stock managed to close at $48.4, a loss of 0.49% for the day. On the previous day, the stock had closed at $48.64. The total traded volume of the day was 652,642 shares.
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Companys two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for womens health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective, orally-active, non-peptide CRF receptor antagonist.